Vaishali Pharma Ltd vs Viyash Scientific Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Vaishali Pharma Ltd is ₹ 7.61 as of 30 Apr 15:30 . The P/E Ratio of Vaishali Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Viyash Scientific Ltd changed from 62.7 on March 2021 to 150.3 on March 2025 . This represents a CAGR of 19.11% over 5 years The Market Cap of Vaishali Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Viyash Scientific Ltd changed from ₹ 5983 crore on March 2021 to ₹ 3273 crore on March 2025 . This represents a CAGR of -11.36% over 5 years The revenue of Vaishali Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 25.54 crore. This represent the decline of -100% The revenue of Viyash Scientific Ltd for the Mar '25 is ₹ 403.36 crore as compare to the Dec '25 revenue of ₹ 872.39 crore. This represent the decline of -53.76% The ebitda of Vaishali Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.45 crore. This represent the decline of -100% The ebitda of Viyash Scientific Ltd for the Mar '25 is ₹ 47.56 crore as compare to the Dec '25 ebitda of ₹ 148.35 crore. This represent the decline of -67.94% The net profit of Vaishali Pharma Ltd changed from ₹ 1.28 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of -100.00% The net profit of Viyash Scientific Ltd changed from ₹ 9.06 crore to ₹ 10.38 crore over 7 quarters. This represents a CAGR of 8.08% The Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Viyash Scientific Ltd changed from 38.67 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

About Viyash Scientific Ltd

Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself.
The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on Nov 12, 2003.

FAQs for the comparison of Vaishali Pharma Ltd and Viyash Scientific Ltd

Which company has a larger market capitalization, Vaishali Pharma Ltd or Viyash Scientific Ltd?

Market cap of Vaishali Pharma Ltd is 99 Cr while Market cap of Viyash Scientific Ltd is 8,918 Cr

What are the key factors driving the stock performance of Vaishali Pharma Ltd and Viyash Scientific Ltd?

The stock performance of Vaishali Pharma Ltd and Viyash Scientific Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Vaishali Pharma Ltd and Viyash Scientific Ltd?

As of May 4, 2026, the Vaishali Pharma Ltd stock price is INR ₹7.61. On the other hand, Viyash Scientific Ltd stock price is INR ₹204.15.

How do dividend payouts of Vaishali Pharma Ltd and Viyash Scientific Ltd compare?

To compare the dividend payouts of Vaishali Pharma Ltd and Viyash Scientific Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.